Skip to main content
Fig. 4 | Journal of Biological Engineering

Fig. 4

From: Recombinant baculovirus expressing the FrC-OVA protein induces protective antitumor immunity in an EG7-OVA mouse model

Fig. 4

Therapeutic vaccination with rBV on EG7-OVA-induced tumors in mice. a Schematic of the experimental timeline. b Comparison of the antitumor immunity exhibited by rBV, FrC-OVA-pVAX1-CAG-MCS or wtBV in B6 mice. Mice were subcutaneously injected on day 0 with EG7-OVA cells (5 × 106 cells/mouse). Survival rates of EG7-OVA-injected mice treated with rBV, FrC-OVA-pVAX1-CAG-MCS, wtBV or PBS on days 14 and 21. *P < 0.01 compared with the negative control and wtBV groups. **P < 0.05 compared with the FrC-OVA-pVAX1-CAG-MCS group. Similar results were obtained from two independent experiments with 6 mice per group

Back to article page